0001193125-24-032871.txt : 20240213 0001193125-24-032871.hdr.sgml : 20240213 20240213070103 ACCESSION NUMBER: 0001193125-24-032871 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240209 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AILERON THERAPEUTICS INC CENTRAL INDEX KEY: 0001420565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38130 FILM NUMBER: 24622555 BUSINESS ADDRESS: STREET 1: 738 MAIN STREET STREET 2: UNIT 398 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-995-0900 MAIL ADDRESS: STREET 1: 738 MAIN STREET STREET 2: UNIT 398 CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 d780523d8k.htm 8-K 8-K
AILERON THERAPEUTICS INC NASDAQ false 0001420565 0001420565 2024-02-09 2024-02-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 9, 2024

 

 

Aileron Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-38130   13-4196017

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

738 Main Street #398

Waltham, MA

   02451
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 995-0900

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   ALRN   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On February 9, 2024, the Board of Directors of Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), approved a performance-based cash bonus for the fiscal year ended December 31, 2023 to Brian Windsor, Ph.D., the Company’s President and Chief Operating Officer. This Current Report on Form 8-K is being filed to update the “Bonus” and “Total” columns of the Summary Compensation Table in the Company’s definitive proxy statement for its 2023 annual meeting of stockholders filed with the U.S. Securities and Exchange Commission on January 29, 2024 for Dr. Windsor to reflect the cash bonus amount of $204,375 awarded to Dr. Windsor. For Dr. Windsor, the “Bonus” and “Total” columns for 2023 are each increased by the bonus amount to $204,375 in bonus compensation and $289,642 in total compensation. None of the Company’s other named executive officers received a performance-based cash bonus for the fiscal year ended December 31, 2023.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AILERON THERAPEUTICS, INC.
Date: February 13, 2024     By:  

/s/ Manuel C. Alves-Aivado

      Manuel C. Alves-Aivado, M.D., Ph.D.
      Chief Executive Officer
 EX-101.SCH 2 alrn-20240209.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 alrn-20240209_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 alrn-20240209_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Feb. 09, 2024
Cover [Abstract]  
Entity Registrant Name AILERON THERAPEUTICS INC
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001420565
Document Type 8-K
Document Period End Date Feb. 09, 2024
Entity Incorporation State Country Code DE
Entity File Number 001-38130
Entity Tax Identification Number 13-4196017
Entity Address, Address Line One 738 Main Street #398
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code (617)
Local Phone Number 995-0900
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol ALRN
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports alrn-20240209.xsd alrn-20240209_lab.xml alrn-20240209_pre.xml d780523d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d780523d8k.htm": { "nsprefix": "alrn", "nsuri": "http://www.aileronrx.com/20240209", "dts": { "schema": { "local": [ "alrn-20240209.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "alrn-20240209_lab.xml" ] }, "presentationLink": { "local": [ "alrn-20240209_pre.xml" ] }, "inline": { "local": [ "d780523d8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-02-09_to_2024-02-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d780523d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-02-09_to_2024-02-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d780523d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.aileronrx.com//20240209/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-24-032871-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-032871-xbrl.zip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end XML 16 d780523d8k_htm.xml IDEA: XBRL DOCUMENT 0001420565 2024-02-09 2024-02-09 AILERON THERAPEUTICS INC NASDAQ false 0001420565 8-K 2024-02-09 DE 001-38130 13-4196017 738 Main Street #398 Waltham MA 02451 (617) 995-0900 false false false false Common Stock, $0.001 par value per share ALRN false